Загрузка...
Tamoxifen and the Risk of Ovarian Cancer in BRCA1 Mutation Carriers
OBJECTIVE: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2009
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3756313/ https://ncbi.nlm.nih.gov/pubmed/19577280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2009.06.012 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|